Arno Therapeutics

99 articles about Arno Therapeutics

• Arno Therapeutics Reports Positive Interim Results from Glioblastoma Study; Phase II Enrollment to Continue

  6/23/2011

• Arno Therapeutics Announces the Appointment of Mr. Glenn Mattes as President and Chief Executive Officer

  4/28/2011

• Arno Therapeutics Raises $15 Million in Private Placement To Advance Clinical Development of Oncology Compounds

  9/14/2010

• Arno Therapeutics Announces Dosing of First Patient in a Phase I/IIa Study of AR-42, a Broad Spectrum Histone and Non-Histone Deacetylation Inhibitor (pan-DAC)

  6/17/2010

• Arno Therapeutics Announces Enrollment of First Patient in Phase II Study of AR-67 in Patients with Glioblastoma Multiforme (GBM)

  12/17/2009

• Arno Therapeutics Announces Poster Presentation at American Society of Hematology Annual Meeting Demonstrating Anti-Leukemic Stem Cell Activity of AR-42

  12/16/2009

• Arno Therapeutics Announces Dosing of First Patient in Phase I of AR-12, a PDK-1 Inhibitor Targeting the PI3K/Akt Pathway

  8/27/2009

• Arno Therapeutics Announces Enrollment of First Patient in Phase II Study of AR-67 (formerly DB-67) in Patients with Myelodysplastic Syndrome

  7/23/2009

• Arno Therapeutics Announces Three Poster Presentations at American Society of Clinical Oncology Annual Meeting

  5/27/2009

• FDA Accepts Arno Therapeutics' IND for AR-12 a PDK1 Inhibitor That Blocks the PI3K/Akt Pathway

  5/11/2009

• Arno Therapeutics Reports 2008 Year-End Financial Results

  3/31/2009

• FDA Accepts IND for Arno Therapeutics' Pan-DAC / Akt Inhibitor, AR-42

  3/17/2009

• Arno Therapeutics Announces Third Quarter 2008 Financial Results

  11/14/2008

• Arno Therapeutics Appoints William F. Hamilton to Board of Directors

  10/30/2008

• Arno Therapeutics Announces Appointment of Roger G. Berlin, MD, as Chief Executive Officer and Director

  9/3/2008

• Arno Therapeutics Announces Second Quarter 2008 Financial Results

  8/19/2008

• Arno Therapeutics Announces Appointment of Brian Lenz, CPA as Chief Financial Officer

  8/14/2008

• Arno Therapeutics Announces New Ticker Symbol

  7/17/2008

• Arno Therapeutics Completes $18 Million Financing and Reverse Merger with Laurier International, Inc.

  6/4/2008